comparemela.com

Latest Breaking News On - Infective research - Page 2 : comparemela.com

Recce Pharmaceuticals to Receive Australian Grant

Recce receives a grant intent from the Australian Patent Office for an antivirus agent targeting mega bugs coronavirus, SARS, and HIV, growing in big pharmaceutical markets across the world.

China
Australia
Japan
Cross-river
Queensland
Hong-kong
Sydney
New-south-wales
Australian
Phil-sutton
James-graham
Callum-newman

Experts present on infectious disease at Distinguished Seminar Speaker Series beginning Aug. 31

Experts present on infectious disease at Distinguished Seminar Speaker Series beginning Aug. 31
vt.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vt.edu Daily Mail and Mail on Sunday newspapers.

Maryland
United-states
Virginia
Kansas
Nebraska
Jonathan-auguste
Earla-forsythe
Juergen-richt
Shawn-chen
Rodrigo-almedia
Berkeley-hildebrand-laumeister
Ww-caruth-jr

Utility Therapeutics Ltd.: UTILITY Therapeutics Announces Scientific Advisory Board

Utility Therapeutics Ltd.: UTILITY Therapeutics Announces Scientific Advisory Board SAB includes key opinion leaders for infectious diseases and urinary tract infections LONDON, UK / ACCESSWIRE / May 11, 2021 / UTILITY therapeutics Ltd., a biotechnology company focused on the U.S. development and commercialization of two European-approved antibiotics for the treatment of urinary tract infections (UTI), announced today that it has established a Scientific Advisory Board (SAB) that will be chaired by Keith A. Rodvold, PharmD and Distinguished Professor of Pharmacy at the College of Medicine at the University of Illinois in Chicago. We are honored to have such a prestigious and experienced group of medical and industry experts join our Scientific Advisory Board, stated Tom Hadley, President and Chief Commercial Officer of UTILITY therapeutics. Their guidance will be extremely valuable as we advance our two product candidates for the treatment of UTIs. We look forward to working

New-york
United-states
Hartford-hospital
Connecticut
Albany-college-of-pharmacy
University-of-illinois
Illinois
Michigan
Chicago
London
City-of
United-kingdom

UTILITY Therapeutics Announces Scientific Advisory Board

UTILITY Therapeutics Announces Scientific Advisory Board ACCESSWIRE SAB includes key opinion leaders for infectious diseases and urinary tract infections LONDON, UK / ACCESSWIRE / May 11, 2021 / UTILITY therapeutics Ltd., a biotechnology company focused on the U.S. development and commercialization of two European-approved antibiotics for the treatment of urinary tract infections (UTI), announced today that it has established a Scientific Advisory Board (SAB) that will be chaired by Keith A. Rodvold, PharmD and Distinguished Professor of Pharmacy at the College of Medicine at the University of Illinois in Chicago. We are honored to have such a prestigious and experienced group of medical and industry experts join our Scientific Advisory Board, stated Tom Hadley, President and Chief Commercial Officer of UTILITY therapeutics. Their guidance will be extremely valuable as we advance our two product candidates for the treatment of UTIs. We look forward to working with our SAB to

New-york
United-states
Hartford-hospital
Connecticut
Albany-college-of-pharmacy
University-of-illinois
Illinois
Michigan
Chicago
London
City-of
United-kingdom

Eye and cystic fibrosis drugs identified among drugs with potential to guide new COVID-19 treatments

Eye and cystic fibrosis drugs identified among drugs with potential to guide new COVID-19 treatments
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Australia
Ghana
Gold-coast
Australian
Thomas-haselhorst
Michael-jennings
Benjamin-bailly
Griffith-university
Infective-research
German-fraunhofer-international-consortium-for-anti
Institute-for-glycomics
Prof-thomas-haselhorst
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.